TSP-1 has been identified as an activator of TGF-β, found increased in the glomeruli of DN patients, co-expressed with p-SMAD2/3, and its inhibition has resulted in reduced renal impairment and proteinuria (Hohenstein et al., 2008). The gene discussed is TGFB1; the disease is liver dysplastic nodule.